jRCT2071210042进行中（未招募）不适用
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Injectable Favipiravir in Healthy Subjects
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 主要终点
- Adverse events
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 39age old under（—）
- 性别
- Male
入选标准
- •(1) Subjects between 20 and 39 years of age (inclusive) at informed consent
- •(2) Gender: Male subjects
- •(3) Subjects with BMI in the range of 18.5 or more and less than 30.0 kg/m2 and body weight 55 kg or more
- •(4) Subjects who understand the objectives of the study, volunteer to participate in the study, and are able to provide written informed consent
排除标准
- •(1) Subjects with a medical history of gastrointestinal, skin, renal, hepatic, neurological, hematological, endocrine, cancer, respiratory, immunological, psychological, cardiovascular, or other diseases that is considered to affect safety of the subjects and evaluation of the study drug by the principal investigator or subinvestigator
- •(2) Subjects with a history of surgery or a disease condition that is considered by the principal investigator or subinvestigator to affect the distribution, metabolism, and excretion of the study drug
- •(3) Subjects who have previously received favipiravir
- •(4) Subjects who are deemed to be ineligible for the study by the principal investigator or subinvestigator
结局指标
主要结局
Adverse events
To evaluate the safety and tolerability
Laboratory tests
To evaluate the safety and tolerability
Twelve-lead electrocardiogram
To evaluate the safety and tolerability
Vital signs
To evaluate the safety and tolerability
次要结局
- Urinary excretion rate of favipiravir and M1
- PK parameters of favipiravir and M1 by non-compartmental analysis
- Plasma concentration versus time profile of favipiravir and its metabolite (M1)
- Dose proportionality of PK of favipiravir using Cmax and AUCinf
研究者
相似试验
进行中（未招募）
不适用
Multiple-dose Study of Injectable FavipiravirjRCT2071210126FUJIFILM Toyama Chemical Co., Ltd.24
已完成
不适用
A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects.Asthma10010613NL-OMON35064GlaxoSmithKline6
招募中
3 期
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
招募中
2 期
Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N23Ardabil University of Medical Sciences100